$PBH

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pbh-20260810 0001295947 false 0001295947 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of ea

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.

Prestige Consumer Healthcare (PBH) reported Q1 fiscal 2027 sales of about $266 million, up 6.5%, with growth led by GI brands such as Dramamine and Fleet and skin care brands including Compound W. Adjusted EPS rose to $0.98 and adjusted free cash flow reached $83.7 million. PBH also completed acquisitions of the Breathe Right portfolio (closed June 12) and LaCorium (July 1).

Premium Brands Holdings (TSX: PBH) reported record Q2 2026 results. Revenue rose to $2.4B, up 26.3% year over year, with 7.5% organic sales growth. Adjusted EBITDA from continuing operations increased to $225.0M and adjusted EPS to $1.53. The company declared a $0.85 dividend for Q3 and revised 2026 guidance due to delayed promotions/new product launches.

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991fy27-q1earningsr.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results • Q1 Revenue of $265.7 million up 6.5% versus prior year • Q1 Organic sales growth of 3.2%, exceeding expectations • Q1 Diluted EPS o

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 tm2620415d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 INDENTURE Dated as of July 15, 2026 Among PRESTIGE BRANDS, INC., as the Issuer, the Guarantors from time to time party hereto and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee 6.250% SENIOR NOTES DUE 2034 TABLE OF

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-99.1 2 exhibit991prestige-launchp.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes July 6, 2026 TARRYTOWN, N.Y., July 6 , 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) a

Prestige Consumer Healthcare (NYSE:PBH) said it completed on June 15 the $1.045 billion acquisition of the Breathe Right brand and other brands from Foundation Consumer Healthcare. PBH expects the deal to expand its OTC portfolio; Breathe Right is projected to generate about $200M revenue and $95M core profit in 2025.

The article says Alphabet’s inclusion in the Dow and Berkshire Hathaway’s increased holding drew attention, but focuses on Prestige Consumer Healthcare (PBH). It reports PBH closed a $1.045B acquisition of Breathe Right and other OTC brands on June 15, adding ~$200M annual revenue and ~$95M EBITDA, and notes net leverage ~4.0x at closing.

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001295947 0001295947 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor